Askal Ali to United States
This is a "connection" page, showing publications Askal Ali has written about United States.
Connection Strength
0.423
-
Nkemdirim Okere A, Li T, Theran C, Nyasani E, Ali AA. Evaluation of factors predicting transition from prediabetes to diabetes among patients residing in underserved communities in the United States - A machine learning approach. Comput Biol Med. 2025 Mar; 187:109824.
Score: 0.106
-
Abegaz TM, Diaby V, Sherbeny F, Ali AA. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clin Drug Investig. 2022 Jun; 42(6):501-511.
Score: 0.088
-
Ali AA, Tawk R, Xiao H, Semykina A, Montero AJ, Moussa RK, Popoola O, Diaby V. Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul; 22(5):735-741.
Score: 0.086
-
Ali AA, Xiao H, Tawk R, Campbell E, Semykina A, Montero AJ, Diaby V. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Curr Med Res Opin. 2017 02; 33(2):391-400.
Score: 0.060
-
Zhang X, Dutton M, Liu R, Ali AA, Sherbeny F. Deep Learning-Based Survival Analysis for Receiving a Steatotic Donor Liver Versus Waiting for a Standard Liver. Transplant Proc. 2023 Dec; 55(10):2436-2443.
Score: 0.024
-
Luque JS, Kiros GE, Vargas M, Jackson DR, Matthew OO, Austin TD, Tawk R, Ali AA, Harris CM, Wallace K, Gwede CK. Association of Preventive Care Attitudes and Beliefs with Colorectal Cancer Screening History among African American Patients of Community Health Centers. J Cancer Educ. 2023 12; 38(6):1816-1824.
Score: 0.024
-
Diaby V, Ali A, Babcock A, Fuhr J, Braithwaite D. Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions. J Manag Care Spec Pharm. 2021 Sep; 27(9-a Suppl):S22-S29.
Score: 0.021
-
Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
Score: 0.015